1 Recommendations

1.1 Sacituzumab govitecan is recommended, within its marketing authorisation, as an option for treating unresectable triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease. It is recommended only if the company provides sacituzumab govitecan according to the commercial arrangement.

Why the committee made these recommendations

Usual treatment for triple-negative locally advanced or metastatic breast cancer is chemotherapy.

Clinical trial evidence shows that sacituzumab govitecan increases how long people have before their disease gets worse and how long they live compared with chemotherapy.

Sacituzumab govitecan meets NICE's criteria to be considered a life-extending treatment at the end of life. The cost-effectiveness estimates are within what NICE usually considers an acceptable use of NHS resources. Therefore, it is recommended.

  • National Institute for Health and Care Excellence (NICE)